EA201101525A1 - Фармацевтическая композиция - Google Patents
Фармацевтическая композицияInfo
- Publication number
- EA201101525A1 EA201101525A1 EA201101525A EA201101525A EA201101525A1 EA 201101525 A1 EA201101525 A1 EA 201101525A1 EA 201101525 A EA201101525 A EA 201101525A EA 201101525 A EA201101525 A EA 201101525A EA 201101525 A1 EA201101525 A1 EA 201101525A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- rotigotine
- relates
- pharmaceutical composition
- salts
- locomotor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Radiology & Medical Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Изобретение относится к новым солям 6-(пропил(2-тиофен-2-илэтил)амино)тетралин-1-ола (ротиготина), к их применению в качестве лекарственного препарата, например, для лечения расстройств ЦНС, таких как болезнь Паркинсона, RLS, фибромиалгия и/или депрессия, особенно путем локомоторного введения. Данное изобретение относится к фармацевтическим составам, пригодным для ионофореза, который обеспечивает эффективную ионофоретическую доставку ротиготина по меньшей мере в одну ткань-мишень. Эти составы характеризуются также растворимостью солей в водных растворах (от хорошей до отличной).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09008401A EP2281559A1 (en) | 2009-06-26 | 2009-06-26 | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
PCT/EP2010/003796 WO2010149363A2 (en) | 2009-06-26 | 2010-06-24 | A pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201101525A1 true EA201101525A1 (ru) | 2012-08-30 |
EA021940B1 EA021940B1 (ru) | 2015-10-30 |
Family
ID=41314650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201101525A EA021940B1 (ru) | 2009-06-26 | 2010-06-24 | Фармацевтическая композиция на основе дигидрофосфата ротиготина |
Country Status (12)
Country | Link |
---|---|
US (2) | US8754120B2 (ru) |
EP (2) | EP2281559A1 (ru) |
JP (1) | JP5771607B2 (ru) |
KR (1) | KR20120092548A (ru) |
CN (2) | CN103319453A (ru) |
AU (1) | AU2010265087B2 (ru) |
BR (1) | BRPI1015939A2 (ru) |
CA (1) | CA2761427C (ru) |
EA (1) | EA021940B1 (ru) |
IL (1) | IL216256A0 (ru) |
MX (1) | MX2011014025A (ru) |
WO (1) | WO2010149363A2 (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10359528A1 (de) * | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
CN101970422B (zh) * | 2007-11-28 | 2014-10-22 | Ucb制药有限公司 | 罗替高汀的多晶型物 |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
ME03053B (me) | 2009-12-22 | 2018-10-20 | Ucb Biopharma Sprl | Polivinilpirolidon za stabilizaciju čvrste disperzije nekristalnog oblika rotigotina |
EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
BR112015032929B1 (pt) | 2013-07-03 | 2022-08-23 | Lts Lohmann Therapie-Systeme Ag | Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico |
CN106456567A (zh) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 在经皮递送系统中调节活性剂释放的方法 |
US11752110B2 (en) | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
CN106456566B (zh) * | 2014-05-20 | 2020-06-16 | Lts勒曼治疗系统股份公司 | 含罗替戈汀的经皮递送系统 |
CN111491713B (zh) * | 2017-10-18 | 2022-07-15 | 乔瓦尼·巴尔科 | 用于以液态溶液或以气体形式产生氧和/或氮的活性簇的方法和设备 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5177112A (en) | 1983-01-03 | 1993-01-05 | Whitby Research, Inc. | Substituted 2-aminotetralins |
US5989586A (en) | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
US5382596A (en) | 1993-08-05 | 1995-01-17 | Whitby Research, Inc. | Substituted 2-aminotetralins |
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
AR026505A1 (es) | 1999-11-23 | 2003-02-12 | Aderis Pharmaceuticals Inc | Proceso mejorado para la preparacion de aminotetralinas sustituidas con nitrogeno |
DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
US20030026830A1 (en) | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
US20030027793A1 (en) | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
DE60100595T2 (de) | 2001-05-08 | 2004-06-24 | Lts Lohmann Therapie-Systeme Ag | Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson |
FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
US20060263419A1 (en) | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
EP1494664A2 (en) | 2002-04-18 | 2005-01-12 | Pharmacia Corporation | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease |
DE10220230A1 (de) | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
US20040048779A1 (en) | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
US20060216336A1 (en) | 2002-05-07 | 2006-09-28 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
US8246980B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
DE10234673B4 (de) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
US8211462B2 (en) | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
DE60204229T2 (de) | 2002-12-02 | 2006-02-02 | Schwarz Pharma Ag | Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
DE10334187A1 (de) | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
DE10361259A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
US20050197385A1 (en) | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
TWI392670B (zh) | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
EP1987815A1 (en) | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
WO2009063171A1 (en) * | 2007-11-16 | 2009-05-22 | Pliva Hrvatska D.O.O. | Novel rotigotine salts |
CN101970422B (zh) | 2007-11-28 | 2014-10-22 | Ucb制药有限公司 | 罗替高汀的多晶型物 |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
ME03053B (me) | 2009-12-22 | 2018-10-20 | Ucb Biopharma Sprl | Polivinilpirolidon za stabilizaciju čvrste disperzije nekristalnog oblika rotigotina |
-
2009
- 2009-06-26 EP EP09008401A patent/EP2281559A1/en not_active Withdrawn
-
2010
- 2010-06-24 BR BRPI1015939A patent/BRPI1015939A2/pt not_active IP Right Cessation
- 2010-06-24 AU AU2010265087A patent/AU2010265087B2/en not_active Ceased
- 2010-06-24 EP EP10728600A patent/EP2445496A2/en not_active Withdrawn
- 2010-06-24 MX MX2011014025A patent/MX2011014025A/es active IP Right Grant
- 2010-06-24 CA CA2761427A patent/CA2761427C/en not_active Expired - Fee Related
- 2010-06-24 EA EA201101525A patent/EA021940B1/ru not_active IP Right Cessation
- 2010-06-24 CN CN2013102401100A patent/CN103319453A/zh active Pending
- 2010-06-24 KR KR1020127002003A patent/KR20120092548A/ko not_active Application Discontinuation
- 2010-06-24 US US13/379,333 patent/US8754120B2/en not_active Expired - Fee Related
- 2010-06-24 CN CN2010800280214A patent/CN102458397A/zh active Pending
- 2010-06-24 JP JP2012516573A patent/JP5771607B2/ja not_active Expired - Fee Related
- 2010-06-24 WO PCT/EP2010/003796 patent/WO2010149363A2/en active Application Filing
-
2011
- 2011-11-10 IL IL216256A patent/IL216256A0/en unknown
-
2014
- 2014-03-31 US US14/230,177 patent/US9034914B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2010149363A3 (en) | 2011-03-24 |
CN103319453A (zh) | 2013-09-25 |
IL216256A0 (en) | 2012-01-31 |
JP2012530741A (ja) | 2012-12-06 |
US20120101146A1 (en) | 2012-04-26 |
BRPI1015939A2 (pt) | 2016-09-27 |
JP5771607B2 (ja) | 2015-09-02 |
US9034914B2 (en) | 2015-05-19 |
EP2445496A2 (en) | 2012-05-02 |
KR20120092548A (ko) | 2012-08-21 |
MX2011014025A (es) | 2012-02-22 |
US20140243386A1 (en) | 2014-08-28 |
EP2281559A1 (en) | 2011-02-09 |
AU2010265087B2 (en) | 2015-01-22 |
EA021940B1 (ru) | 2015-10-30 |
AU2010265087A1 (en) | 2011-12-01 |
CA2761427A1 (en) | 2010-12-29 |
CA2761427C (en) | 2016-11-22 |
CN102458397A (zh) | 2012-05-16 |
US8754120B2 (en) | 2014-06-17 |
WO2010149363A2 (en) | 2010-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201101525A1 (ru) | Фармацевтическая композиция | |
PH12019501215A1 (en) | Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid | |
TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
MX2019009255A (es) | Proteínas quiméricas dirigidas y sus usos. | |
MY155649A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
BR112015019720A2 (pt) | inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c | |
MX2013002822A (es) | Profarmacos que comprenden un conjugado de conector de exendina. | |
ME02414B (me) | Tretman kronove bolesti lakvinimodom | |
TN2012000011A1 (en) | Prodrugs comprising an insulin linker conjugate | |
MX2009008531A (es) | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. | |
JO2686B1 (en) | Vehicles | |
MX2014014902A (es) | Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas. | |
HK1154587A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
MX2009004362A (es) | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. | |
EA201290191A1 (ru) | N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ | |
UA104489C2 (ru) | Соединения для лечения дислипидемии и родственных болезней | |
EA200970287A1 (ru) | Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты | |
EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
MY163516A (en) | Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents | |
DK1885333T3 (da) | Farmaceutisk formulering af apomorphin til bukkal indgivelse | |
EA201171088A1 (ru) | Лечение дискинезии при различных расстройствах | |
MX2017015734A (es) | Profarmacos que comprenden un conjugado de acido hialuronico enlazador agonista dual de glp-1/glucagon. | |
WO2009025785A3 (en) | Cb2 receptor ligands for the treatment of pain | |
BR112012028321A2 (pt) | "compostos análogos de desazadesferrotiocina e desazadesferrotiocina poliéter como agentes de quelação de metal, composição farmacêutica e usos dos ditos compostos" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |